|

Is DexCom a go-to health care stock? [Video]

DexCom, Inc. is a global company headquartered in San Diego, California, that focuses on the development, manufacturing, and distribution of continuous glucose monitoring (CGM) systems for managing diabetes. These systems enable individuals with diabetes to monitor their blood glucose levels consistently throughout the day, aiding in effective diabetes management and treatment decision-making. With a strong international presence, DexCom serves customers worldwide, contributing significantly to advancements in diabetes care through its innovative CGM technology.

When there are recessionary risks healthcare companies can remain profitable as consumers understandably prioritize health care. DexCom has some impressive seasonal patterns outlined which have been found using the Seasonax screener feature.

Over the last 15 years, DexCom has gained 14 out of 15 times. With a very strong seasonal pattern and excellent annualized returns of over 115% and an average of 13.18%, the main question is if it is worth looking at DexCom as we head into the summer months.

Major Trade Risks: The major trade risk here is for stock-specific news to DexCom or if the seasonal pattern fails to hold up this year.


Learn more about HYCM


Author

Giles Coghlan LLB, Lth, MA

Giles is the chief market analyst for Financial Source. His goal is to help you find simple, high-conviction fundamental trade opportunities. He has regular media presentations being featured in National and International Press.

More from Giles Coghlan LLB, Lth, MA
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD moves sideways below 1.1800 on Christmas Eve

EUR/USD struggles to find direction and trades in a narrow channel below 1.1800 after posting gains for two consecutive days. Bond and stock markets in the US will open at the usual time and close early on Christmas Eve, allowing the trading action to remain subdued. 

GBP/USD keeps range around 1.3500 amid quiet markets

GBP/USD keeps its range trade intact at around 1.3500 on Wednesday. The Pound Sterling holds the upper hand over the US Dollar amid pre-Christmas light trading as traders move to the sidelines heading into the holiday season. 

Gold retreats from record highs, trades below $4,500

Gold retreats after setting a new record-high above $4,520 earlier in the day and trades in a tight range below $4,500 as trading volumes thin out ahead of the Christmas break. The US Dollar selling bias remains unabated on the back of dovish Fed expectations, which continues to act as a tailwind for the bullion amid persistent geopolitical risks.

Bitcoin slips below $87,000 as ETF outflows intensify, whale participation declines

Bitcoin price continues to trade around $86,770 on Wednesday, after failing to break above the $90,000 resistance. US-listed spot ETFs record an outflow of $188.64 million on Tuesday, marking the fourth consecutive day of withdrawals.

Economic outlook 2026-2027 in advanced countries: Solidity test

After a year marked by global economic resilience and ending on a note of optimism, 2026 looks promising and could be a year of solid economic performance. In our baseline scenario, we expect most of the supportive factors at work in 2025 to continue to play a role in 2026.

Avalanche struggles near $12 as Grayscale files updated form for ETF

Avalanche trades close to $12 by press time on Wednesday, extending the nearly 2% drop from the previous day. Grayscale filed an updated form to convert its Avalanche-focused Trust into an ETF with the US Securities and Exchange Commission.